Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Long-Term Deferred Tax (2022 - 2023)

InMed Pharmaceuticals (INM) has 2 years of Long-Term Deferred Tax data on record, last reported at $21.0 million in Q2 2023.

  • For Q2 2023, Long-Term Deferred Tax rose 29184.45% year-over-year to $21.0 million; the TTM value through Jun 2023 reached $21.0 million, up 29184.45%, while the annual FY2023 figure was $21.0 million, 29184.45% up from the prior year.
  • Long-Term Deferred Tax reached $21.0 million in Q2 2023 per INM's latest filing, up from $71806.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $21.0 million in Q2 2023 and bottomed at $71806.0 in Q2 2022.